Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents

Hepatology

Volumn 63, Issue 3, 2016, Pages 1058-1059

  Ceccherini Silberstein, Francesca ^a   Di Maio, Velia Chiara ^a   Aragri, Marianna ^a   Ciotti, Marco ^b   Cento, Valeria ^a   Perno, Carlo Federico ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; NONSTRUCTURAL PROTEIN 3;

ACCURACY; ANTIVIRAL THERAPY; ASSAY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; GENETICS; GENOTYPING TECHNIQUE; HEPACIVIRUS; MOLECULARLY TARGETED THERAPY; SEQUENCE ANALYSIS;

GENOTYPING TECHNIQUES; HEPACIVIRUS; MOLECULAR TARGETED THERAPY; SEQUENCE ANALYSIS, RNA;

EID: 84936817310     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27895     Document Type: Letter

References (5)

1. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-1192.
2. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014. http://www.hcvguidelines.org. Accessed February 2015.
3. Benedet M, Adachi D, Wong A, Wong S, Pabbaraju K, Tellier R, et al. The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: a 1 year analysis. J Clin Virol 2014;60:301-304.
4. Cento V, Landonio S, De Luca F, Di Maio VC, Micheli V, Mirabelli C, et al. A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. Antivir Ther 2013;18:645-648.
5. Liu CH, Liang CC, Liu CJ, Lin CL, Su TH, Yang HC, et al. Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for hepatitis C virus genotyping. J Clin Microbiol 2015;53:1754-1757.